Latest News for: merck & co inc).

Edit

Biliary Tract Cancer Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | ...

GetNews 29 Jan 2025
... Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Merck & Co Inc)

Public Technologies 29 Jan 2025
) Ownership Submission FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10 ... Washington, D.C ... OMB Number ... 0.5 ... Smart Dalton. 2 ... Merck & Co., Inc ... 6 ... Merck & Co. Inc.
Edit

Glaucoma Treatment Market to Reach USD 8.0 Billion by 2033 at a 3.2% of CAGR Amid Rising Prevalence of the Disease

Pharmiweb 29 Jan 2025
AERIE Pharmaceuticals, Inc.; Cipla Inc.; Akorn Operating Company LLC; AbbVie; Bausch & Lomb Incorporated; Inoteck Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Santen ...
Edit

Cell Culture Media Market to Reach USD 6,699.93 Million by 2034, Expanding at a CAGR of 6.66%

Pharmiweb 29 Jan 2025
Key Companies in the Market Avantor, Inc. Thermo Fisher Scientific, Inc. Caisson Laboratories Inc. Becton Dickinson and Company Lonza Group AG Bio-Rad Laboratories, Inc ... Merck & Co., Inc ... Future Market Insights, Inc ... Future Market Insights Inc.
Edit

Merck Issues Statement on GARDASIL® Litigation - Merck.com (Merck & Co Inc)

Public Technologies 28 Jan 2025
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA. This statement of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking ...
Edit

FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)

Pharmiweb 28 Jan 2025
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA. This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Edit

Pancreatic Cancer Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight ...

GetNews 28 Jan 2025
Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others.
Edit

Idiopathic Pulmonary Fibrosis Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight ...

GetNews 28 Jan 2025
In October 2024, Tvardi Therapeutics, Inc ... Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., MediciNova Inc., Jubliant Pharma Limited (Jubliant Cadista Limited), Merck & Co.
Edit

Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Pharmiweb 28 Jan 2025
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year ... Komen, said ... Notes ... Enhertu ... AstraZeneca with MSD (Merck & Co., Inc ... 1-72 ... .
Edit

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Pharmiweb 27 Jan 2025
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA. This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Edit

Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight ...

GetNews 27 Jan 2025
In December 2024, Armata Pharmaceuticals, Inc ... In May 2024, Pfizer Inc ... BiomX, Inc ... Genentech, Inc ... Key companies developing therapies for Chronic Pulmonary Infections are - Merck & Co., Inc., F.
Edit

Migraine Pipeline 2024: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight | ...

GetNews 24 Jan 2025
Key companies developing therapies for Migraine are - GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co., Teva Pharmaceuticals, Novartis AG, Eisai Co., Ltd., Abbott Laboratories, and others.

Most Viewed

×